2016
Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A
Hartley M, Bourreau E, Rossi M, Castiglioni P, Eren R, Prevel F, Couppié P, Hickerson S, Launois P, Beverley S, Ronet C, Fasel N. Leishmaniavirus-Dependent Metastatic Leishmaniasis Is Prevented by Blocking IL-17A. PLOS Pathogens 2016, 12: e1005852. PMID: 27658195, PMCID: PMC5033371, DOI: 10.1371/journal.ppat.1005852.Peer-Reviewed Original ResearchIL-17AMurine modelMetastatic leishmaniasisDisease chronicityHuman patientsInflammatory cytokines IL-17AIL-17A inhibitionPotent innate immunogenPresence of LRV1Cytokines IL-17AAbsence of IFNMetastatic complicationsImmunologic mechanismsStandard therapyCytokines IFNPrognostic valueOpen ulcerationDisease outcomeCutaneous leishmaniasisSecondary sitesSignificant associationLeishmania parasitesTherapeutic promiseLeishmaniasisLRV1
2014
The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis
Hartley M, Drexler S, Ronet C, Beverley S, Fasel N. The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends In Parasitology 2014, 30: 412-422. PMID: 24954794, PMCID: PMC4287268, DOI: 10.1016/j.pt.2014.05.006.Peer-Reviewed Original ResearchConceptsInnate immune systemImmune systemSelf-healing cutaneous lesionsPattern recognition receptorsFacial mucosaMetastatic leishmaniasisMetastatic diseasePapular rashCutaneous lesionsSuch diverse pathologiesCutaneous systemHost immunocompetenceGranulomatous nodulesParasitic infectionsRecognition receptorsPotential associationCutaneous leishmaniasesDiverse pathologiesMillions of peoplePathologyMultiple secondary sitesSecondary sitesRashUlcerationMetastasis
2013
The therapeutic potential of immune cross‐talk in leishmaniasis
Hartley M, Kohl K, Ronet C, Fasel N. The therapeutic potential of immune cross‐talk in leishmaniasis. Clinical Microbiology And Infection 2013, 19: 119-130. PMID: 23398405, DOI: 10.1111/1469-0691.12095.Peer-Reviewed Original ResearchConceptsMetastatic leishmaniasisCutaneous leishmaniasisLeishmania parasitesSelf-healing lesionsProtozoan parasitic diseaseEffective antileishmanial drugsSpecies of LeishmaniaDestructive lesionsImmune homeostasisCurrent treatmentTherapeutic strategiesImmune pathwaysNew drug targetsTherapeutic potentialParasitic diseasesAntileishmanial drugsLeishmaniasisLesionsPrevalent formDiseaseDrug targetsRNA virusesTreatmentVariable effectsParasites
2012
Leishmania RNA virus: when the host pays the toll
Hartley M, Ronet C, Zangger H, Beverley S, Fasel N. Leishmania RNA virus: when the host pays the toll. Frontiers In Cellular And Infection Microbiology 2012, 2: 99. PMID: 22919688, PMCID: PMC3417650, DOI: 10.3389/fcimb.2012.00099.Peer-Reviewed Original ResearchConceptsToll-like receptor 3Mucocutaneous leishmaniasisHyper-inflammatory immune responseLeishmania parasitesPotent innate immunogenExperimental animal modelsType 1 interferonLeishmania RNA virusAnti-leishmanial drugsMetastatic leishmaniasisDestructive inflammationMetastatic complicationsMetastatic diseaseInflammatory cascadeInflammatory stateRNA virusesSecondary lesionsImmune responseAnimal modelsClinical isolatesDisease severityReceptor 3Leishmania guyanensisMetastatic factorsClinical interventions